Apellis updates on 8 retinal vasculitis events with SYFOVRE; recommends switching to 18-gauge filter needle

Apellis Pharmaceuticals, Inc.

Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.
Last confirmed event on June 20; over 32,000 vials distributed since then with no new confirmed events.
One additional occlusive event in May reported after July 29; all events occurred after first injection.
Company recommends discontinuing use of 19-gauge filter needle kits; now exclusively distributing 18-gauge filter needle kits.
Patient outcomes: 1 stable, 2 near baseline, 2 severe vision impairment, 3 pending; two suspected events also reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.